Literature DB >> 9869600

The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome.

M Delvaux1, D Louvel, E Lagier, B Scherrer, J L Abitbol, J Frexinos.   

Abstract

BACKGROUND & AIMS: Visceral hypersensitivity plays a major role in the pathophysiology of inflammatory bowel syndrome (IBS). Opioid kappa receptors on afferent nerves may modulate it and may be the target of new IBS treatments. The aim of this study was to evaluate the effects of fedotozine, a potent and selective kappa agonist, on responses to colonic distention and colonic compliance in patients with IBS.
METHODS: Fourteen patients with IBS (Rome criteria; 50 +/- 12 years; 6 men and 8 women) were included in a randomized double-blind, crossover trial comparing the effect of an intravenous infusion of 100 mg fedotozine or saline on sensory thresholds elicited by left colon phasic distention (4-mm Hg steps for 5 minutes) up to a sensation of abdominal pain. Colonic compliance was compared by the slope of the pressure-volume curves built on placebo and on fedotozine.
RESULTS: In the fedotozine group, thresholds of first perception (28.7 +/- 5.9 mm Hg) and pain (34.7 +/- 5.5 mm Hg) were significantly greater than with placebo (23.3 +/- 4.5 and 29.0 +/- 3.5 mm Hg, respectively; P = 0.0078). Colonic compliance was 9. 20 +/- 3.87 mL. mm Hg-1 with placebo and 8.73 +/- 3.18 mL. mm Hg-1 with fedotozine (not significant).
CONCLUSIONS: Fedotozine increases thresholds of perception of colonic distention in patients with IBS without modifying colonic compliance. Fedotozine seems capable of reversing visceral hypersensitivity observed in these patients and could have some beneficial action on their symptoms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9869600     DOI: 10.1016/s0016-5085(99)70226-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  45 in total

1.  Some of the challenges in drug development for irritable bowel syndrome.

Authors:  E A Mayer
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 2.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

4.  Opioid-induced bowel dysfunction.

Authors:  Howard Y Chang; Anthony J Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

Review 5.  Acupuncture for functional gastrointestinal disorders.

Authors:  Toku Takahashi
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

6.  Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patients.

Authors:  M Di Stefano; E Miceli; A Missanelli; S Mazzocchi; G R Corazza
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

7.  alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 8.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

9.  Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Authors:  Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

10.  Visceral sensitivity in irritable bowel syndrome and healthy volunteers: reproducibility of the rectal barostat.

Authors:  Signe Spetalen; Morten B Jacobsen; Morten H Vatn; Svein Blomhoff; Leiv Sandvik
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.